Researcher at Peking University Cancer Hospital and Institute Publishes New Data on Liposarcomas (Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma).

A study conducted at Peking University Cancer Hospital and Institute in Beijing, China, evaluated the effectiveness of a combined therapeutic strategy using eribulin, anlotinib, and camrelizumab in treating advanced or metastatic retroperitoneal liposarcoma (RLPS). The study included 47 patients with RLPS, and the treatment regimen resulted in a partial response in 18.2% of patients and stable disease in 56.8% of patients. The median progression-free survival was 6.9 months, and the treatment showed promising efficacy and manageable safety, particularly in patients with myxoid liposarcoma. This research provides valuable insights into potential treatment options for RLPS. [Extracted from the article]